美国 · SEC FORM 4
MYRIAD GENETICS INC
MYGN · Nasdaq · CIK 0000899923 · Healthcare · Diagnostics & Research
内部人信号
1 qualifying P purchase group
当前 180 天评分窗口
18 同一窗口内观察到的 Form 4 交易行
1 sales · 16 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
买方广度与集中度
Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 8 additional owner(s) remain in Form 4 申报证据.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-05-14 · Bisaro Paul.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 8,546,169
- 上期报告
- 9,345,601
- 日均成交量
- 2,009,092
- 回补天数
- 4.2
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-14 | Bisaro Paul | 买入 (P) | Common Stock | 7,500 | USD 3.69 | USD 27,675 | SEC 申报 ↗ |
| 2026-03-09 | Raha Samraat S. | 买入 (P) | Common Stock | 40,000 | USD 5.00 | USD 200,000 | SEC 申报 ↗ |
| 2026-02-27 | Phanstiel S. Louise | 买入 (P) | Common Stock | 48,000 | USD 4.66 | USD 223,680 | SEC 申报 ↗ |
| 2026-02-26 | Phanstiel S. Louise | 买入 (P) | Common Stock | 50,407 | USD 4.80 | USD 241,954 | SEC 申报 ↗ |
| 2026-02-25 | Phanstiel S. Louise | 买入 (P) | Common Stock | 6,100 | USD 4.74 | USD 28,914 | SEC 申报 ↗ |
| 2020-11-11 | Phanstiel S. Louise | 买入 (P) | Common Stock | 15,000 | USD 16.62 | USD 249,300 | SEC 申报 ↗ |
Form 4 申报证据
63 transaction lines in the latest 365-day window; 590 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Wheeler Benjamin Richard | 代扣税 (F) | Common Stock | 2,555 | USD 4.01 | USD 10,246 | SEC 申报 ↗ |
| 2026-09-16 | Sikri Vishal | 奖励/授予 (A) | Common Stock | 257,731 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-03 | Fox Jennifer Lynne | 代扣税 (F) | Common Stock | 4,398 | USD 3.23 | USD 14,206 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Wheeler Benjamin Richard | 代扣税 (F) | Common Stock | 2,555 | USD 4.01 | USD 10,246 | SEC 申报 ↗ |
| 2026-09-16 | Sikri Vishal | 奖励/授予 (A) | Common Stock | 257,731 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-03 | Fox Jennifer Lynne | 代扣税 (F) | Common Stock | 4,398 | USD 3.23 | USD 14,206 | SEC 申报 ↗ |
| 2026-08-16 | Wheeler Benjamin Richard | 代扣税 (F) | Common Stock | 8,761 | USD 3.03 | USD 26,546 | SEC 申报 ↗ |
| 2026-06-11 | Raha Samraat S. | 奖励/授予 (A) | Common Stock | 3,542 | USD 3.94 | USD 13,955 | SEC 申报 ↗ |
| 2026-06-11 | Donnelly Brian J | 奖励/授予 (A) | Common Stock | 5,000 | USD 3.94 | USD 19,700 | SEC 申报 ↗ |
| 2026-06-08 | Kumar Rashmi | 卖出 (S) | Common Stock | 15,000 | USD 4.46 | USD 66,900 | SEC 申报 ↗ |
| 2026-06-04 | Skovronsky Daniel | 奖励/授予 (A) | Common Stock | 59,701 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | Reitan Colleen F | 奖励/授予 (A) | Common Stock | 59,701 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | Phanstiel S. Louise | 奖励/授予 (A) | Common Stock | 59,701 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | Newcomer Lee Nisley | 奖励/授予 (A) | Common Stock | 59,701 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | Kumar Rashmi | 奖励/授予 (A) | Common Stock | 59,701 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | Dreismann Heinrich | 奖励/授予 (A) | Common Stock | 59,701 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | Davis Mark Steven | 奖励/授予 (A) | Common Stock | 59,701 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | Bisaro Paul | 奖励/授予 (A) | Common Stock | 59,701 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-01 | Jampa Raj | 奖励/授予 (A) | Common Stock | 251,889 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-14 | Bisaro Paul | 买入 (P) | Common Stock | 7,500 | USD 3.69 | USD 27,675 | SEC 申报 ↗ |
| 2026-05-01 | Donnelly Brian J | 代扣税 (F) | Common Stock | 55,975 | USD 4.80 | USD 268,680 | SEC 申报 ↗ |
| 2026-04-14 | Verratti Mark | 代扣税 (F) | Common Stock | 1,069 | USD 4.91 | USD 5,249 | SEC 申报 ↗ |
| 2026-04-14 | Muzzey Dale | 代扣税 (F) | Common Stock | 946 | USD 4.91 | USD 4,645 | SEC 申报 ↗ |
| 2026-03-22 | Wheeler Benjamin Richard | 代扣税 (F) | Common Stock | 549 | USD 4.58 | USD 2,514 | SEC 申报 ↗ |
| 2026-03-22 | Verratti Mark | 代扣税 (F) | Common Stock | 2,055 | USD 4.58 | USD 9,412 | SEC 申报 ↗ |
| 2026-03-22 | Muzzey Dale | 代扣税 (F) | Common Stock | 2,019 | USD 4.58 | USD 9,247 | SEC 申报 ↗ |
| 2026-03-15 | Wheeler Benjamin Richard | 代扣税 (F) | Common Stock | 3,069 | USD 4.66 | USD 14,302 | SEC 申报 ↗ |
| 2026-03-15 | Verratti Mark | 代扣税 (F) | Common Stock | 14,707 | USD 4.66 | USD 68,535 | SEC 申报 ↗ |
| 2026-03-15 | Muzzey Dale | 代扣税 (F) | Common Stock | 16,732 | USD 4.66 | USD 77,971 | SEC 申报 ↗ |
| 2026-03-15 | Haas Kevin Richard | 代扣税 (F) | Common Stock | 11,737 | USD 4.66 | USD 54,694 | SEC 申报 ↗ |
| 2026-03-14 | Wheeler Benjamin Richard | 代扣税 (F) | Common Stock | 1,097 | USD 4.66 | USD 5,112 | SEC 申报 ↗ |
| 2026-03-14 | Verratti Mark | 代扣税 (F) | Common Stock | 5,418 | USD 4.66 | USD 25,248 | SEC 申报 ↗ |
| 2026-03-14 | Solaiman Shereen | 代扣税 (F) | Common Stock | 5,784 | USD 4.66 | USD 26,953 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | MYGN |
| CIK | 0000899923 |
| 行业 | Healthcare |
| 细分行业 | Diagnostics & Research Yahoo Finance |
| SEC SIC | 2835 In Vitro & In Vivo Diagnostic Substances |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 590 transaction lines from 2020-02-05 to 2026-09-21 6 P purchase lines · 75 S sale lines · 509 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.